The Role of Adjuvant Radiotherapy in High Risk Locally Advanced Differentiated Thyroid Cancer: a 1:1 Randomized Phase III Clinical Trial

What this Trial Is About

This research aims to evaluate the role of additional radiotherapy after surgery for patients with high-risk, locally advanced differentiated thyroid cancer. It is a phase III randomized controlled clinical trial comparing two treatment approaches to see which better prevents cancer recurrence in the lymph nodes and surrounding areas. The study focuses on patients who have had surgery but still have residual cancer tissue, assessing the impact of adding radiotherapy to standard radioiodine therapy (RAI). Participants are randomly assigned to one of two groups: the experimental group receives both radiotherapy and RAI, while the control group receives only RAI. Radiotherapy involves external radiation using advanced techniques such as intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) within six weeks after surgery. Both treatments are administered within six months after surgery. During the study, participants will be monitored for at least five years after surgery to measure outcomes including local-regional recurrence-free survival, recurrence rates, progression-free survival, overall survival, adverse effects, and quality of life. Researchers will conduct regular follow-ups to assess these outcomes and track participants’ health and treatment response over this period. The total participation duration extends through these long-term evaluations to gather comprehensive safety and effectiveness data.

Adjuvant Radiotherapy in High Risk Locally Advanced DTC